937 results about "Tumor growth" patented technology

The present invention relates to a KRASG12D inhibitor and the use thereof. Specifically, provided in the present invention is a compound as shown in formula (I), and the definition of each substituent in the formula is as described in the description. In addition, the present invention further relates to a composition containing the inhibitor and the use thereof. The compound of the present invention has good tumor growth inhibitory activity, and has good safety.

Provided herein are systems, compositions, and methods for generating immunogenic peptides or epitopes from tumor associated antigens (e.g., in vivo or ex vivo). Polynucleotides (e.g., genes) encoding the tumor associated antigens may be edited at selected target sites by nucleobase editors comprising a catalytically-inactive Cas9 and a cytosine deaminase, leading to the expression of heteroclitic or cryptic peptides that are more immunogenic than the native peptide derived from the tumor associated antigens. The heteroclitic or cryptic peptide elicit strong tumor-specific immune response (e.g., T-cell response or B-cell response), which inhibits tumor growth and metastasis.

The invention belongs to the technical field of preparation of anti-tumor drugs, and particularly relates to a coptis root exosome, an extraction method thereof and application of the coptis root exosome in tumor resistance. The coptis root exosome is extracted from coptis roots, the size of the coptis root exosome is 125nm-135nm, and the coptis root exosome is shaped like a vesicle with a lipid bilayer structure. The coptis root exosome has an excellent anti-tumor effect and can remarkably inhibit tumor growth, and the tumor growth inhibition effect is remarkably superior to that of a common extract berberine in coptis roots.

The present application relates to an antibody capable of specifically binding to c-Met or antigen-binding fragment thereof, and an immunoconjugate, a pharmaceutical composition and a multispecific molecule comprising the same. The present application further relates to the use of the antibody specifically binding to c-Met or an antigen-binding fragment thereof and the multispecific molecule. Compared with the control antibody, the bispecific antibody or defucosylated bispecific antibody of the present application can block HGF-dependent TKI resistance; block the proliferation and migration of tumor cells induced by HGF, induce ADCC effect, and inhibit tumor growth in vivo.

The invention provides an ultrasonic activated blood coagulation targeting tumor selective prodrug as well as a preparation method and application thereof. The blood coagulation targeting tumor selective prodrug has a structure as shown in a formula I. The blood coagulation targeting tumor selective prodrug can trigger a blood coagulation cascade reaction by utilizing tumor vascular injury generated by ultrasonic induction so as to realize targeted anchoring of the drug and inhibit off-target diffusion of an active drug; meanwhile, the prodrug is activated by ultrasound, so that the limitation of tumor heterogeneity on the activation of the prodrug can be overcome. According to the technical scheme, selective enrichment of active drugs in tumors can be effectively improved, and toxicity caused by drug off-target is reduced while tumor growth is remarkably inhibited.

The present invention provides an enhanced NK cell, its preparation method and application, belonging to the field of biomedical technology. The present invention uses a compound of quercetin, paclitaxel and resveratrol as a culture medium induction additive to pre-treat NK cells, successfully enhancing the killing toxicity of NK cells against human lung cancer cells and effectively inhibiting tumor growth, opening up a new way for the treatment of lung cancer and having important research value and potential clinical application prospects in the field of tumor immunotherapy.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating triple negative breast cancer and application thereof. The traditional Chinese medicine composition is prepared from the following main active ingredients in parts by mass: 20 to 40 parts of radix astragali seu hedysari, 10 to 20 parts of rhizoma curcumae, 10 to 20 parts of herba hedyotidis diffusae, 5 to 15 parts of fructus aurantii immaturus, 5 to 15 parts of radix bupleuri, 5 to 15 parts of radix paeoniae alba and 5 to 15 parts of liquorice root. Animal experiments show that the traditional Chinese medicine composition can significantly inhibit tumor growth and pulmonary metastasis of triple-negative breast cancer tumor-bearing mice, increase the proportion of CD8 + T lymphocytes in blood, reduce the proportion of MDSCs, significantly down-regulate the expression of pro-inflammatory cytokines such as IL-6, IL-1alpha, CXCL1 and GM-CSF in serum, and cooperate with PD-L1 immunotherapy to achieve a synergistic effect. And the whole blood and liver and kidney function indexes are in a normal range. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively inhibiting the tumor growth and pulmonary metastasis of the triple negative breast cancer, remodeling the immune state of an organism and reducing the release of proinflammatory factors, and is safe, reliable, free of obvious liver and kidney toxicity and blood toxicity and small in side effect.

The invention belongs to the field of biomedicine, and particularly relates to polypeptide for targeted blocking of combination of TRIM25 and BRD7 protein and application of the polypeptide. According to the present invention, based on the minimum binding region PRYSPRY structural domain (439 aa-630 aa) of the TRIM25 and the BRD7 protein, the blocking peptide TB16 capable of specifically blocking the mutual binding of the TRIM25 and the BRD7 protein is screened, such that the ubiquitination degradation of the BRD7 is inhibited, and the stability of the BRD7 tumor inhibition protein is improved. The polypeptide drug TB16 can effectively inhibit breast cancer, nasopharynx cancer, ovarian cancer, lung cancer and liver cancer cell proliferation and breast cancer in-vivo tumor growth, has good anti-solid tumor activity, and is expected to become a new anti-tumor targeting drug.

The invention discloses a colorectal cancer radiotherapy sensitization medicine and application thereof, belongs to the field of biological medicine, and particularly relates to a colorectal cancer radiotherapy sensitization medicine which comprises active pharmaceutical ingredients and a solvent, the active pharmaceutical ingredients comprise doxorubicin and a nitrogen-containing compound, the nitrogen-containing compound comprises quinoline-6-carbohydrazide and N-benzyloxymethyl-4-nitroimidazole, and the nitrogen-containing compound comprises quinoline-6-carbohydrazide and The colorectal cancer radiotherapy sensitization medicine disclosed by the invention focuses on a key driving gene FOXP4 for colorectal cancer radiotherapy resistance, and FOXP4 protein is degraded through a ubiquitin-proteasome way, so that not only can the sensitivity of tumor cells to radiotherapy be remarkably improved and tumor growth be inhibited, but also damage to normal tissues is reduced; moreover, the problem of drug resistance easily generated by a traditional method is effectively avoided, the research and development cost is greatly reduced, clinical transformation is accelerated, and the method has a good clinical application prospect.

The invention discloses an MUC1-CAR-T cell for co-expressing a BTLA / IL-18R chimeric receptor as well as a preparation method and application of the MUC1-CAR-T cell, and belongs to the technical field of biological medicines. The MUC1-CAR-T cell comprises a BTLA / IL-18R chimeric receptor and an MUC1-CAR structure, wherein the BTLA / IL-18R chimeric receptor is a BTLA MUC1 is used as a targeting molecule for CAR-T cell therapy, an extracellular domain of BTLA is connected with a transmembrane domain and an intracellular domain of an IL-18 receptor, and the co-expression BTLA / IL-18R chimeric receptor is designed. Experimental verification shows that the BTLA / IL-18R chimeric receptor can significantly improve the tumor killing ability of MUC1-CAR-T cells, can better inhibit the growth of tumors, and provides a novel immunotherapy strategy for the treatment of pancreatic cancer.

The invention belongs to the technical field of biological medicines, and particularly discloses a nano-engineering T cell membrane coated nano-particle as well as a preparation method and application of the nano-engineering T cell membrane coated nano-particle. Nanoparticles of a specific structure are constructed based on a phospholipid bilayer bionic nanometer platform through a membrane fusion technology, immune clearance caused by phagocytosis of the nanoparticles by macrophages can be avoided through disguise of a T cell membrane, and the blood circulation time is prolonged; the functions of T cells are recovered through specific blocking of immune checkpoint molecules loaded on the immune checkpoint molecules on corresponding immune checkpoint ligands on tumor cells; under ultrasonic radiation, the nano-particles are gradually decomposed and release the sound-sensitive agent to generate a large amount of active oxygen, so that immunogenic death of tumor cells is promoted, more cytotoxic T lymphocytes are recruited to infiltrate into tumor parts, and the recovery of T cell mediated immune response function is facilitated. The synergistic effect of the sound-sensitive agent and the immune checkpoint protein can effectively inhibit tumor growth, induce a long-term immune memory effect and prevent tumor metastasis and recurrence.

The invention discloses a multi-modal image fusion assisted precise tumor needle biopsy guide system, and aims to solve the problem that the traditional needle biopsy guide technology is insufficient in precision. The system innovatively adopts a multi-scale feature fusion algorithm and an adaptive weight fusion strategy, deeply fuses ultrasonic, CT, MRI and other multi-modal images, and comprehensively improves the information amount of the images. Through real-time force feedback and path adjustment, in combination with VR / AR guide interaction, intelligent puncture guide is realized, and safe and accurate operation is guaranteed. Tumor features are extracted by using a deep learning algorithm, accurate tumor recognition and dynamic image analysis are realized, and the tumor growth trend is predicted. According to the system, the precision and success rate of needle biopsy are remarkably improved, the pain of a patient and the medical cost are reduced, powerful support is provided for personalized precise treatment of tumors, and the system has extremely high clinical application value.

The invention belongs to the field of biomedicine, and particularly relates to application of Ikbkb inhibited or knocked-out macrophages in preparation of breast cancer radiotherapy sensitizing drugs. The inventor of the invention proves the effect of the macrophage of which the Ikbkb is inhibited or knocked out in breast cancer radiotherapy for the first time. Compared with the strategy of mainly depending on small molecule drugs or antibodies in the prior art, the tumor growth can be more effectively inhibited after the macrophages in the tumor microenvironment are transformed and the Ikbkb knockout engineered macrophages are subjected to combined radiotherapy, and a brand new solution is provided for overcoming breast cancer radiotherapy resistance.

The invention discloses a PNA-based pre-targeting probe as well as a preparation method and application thereof. The pre-targeting probe based on the PNA comprises a pre-targeting receptor probe PNA-EB-RGD and a ligand probe cPNA labeled by radionuclide, in the PNA-EB-RGD, the PNA is peptide nucleic acid, the EB is Evans blue, and the RGD is RGD peptide; the cPNA is a complementary sequence of the PNA. The PNA-based pre-targeting probe provided by the invention can reduce systemic circulation radiation exposure, obviously reduce blood toxicity and slow down tumor growth.

The invention discloses application of a traditional Chinese medicine composition in preparation of a product for resisting colon cancer and tumor hemagglutinin, and relates to the technical field of biology. The traditional Chinese medicine composition is prepared from the following components: 5-150 parts of American ginseng, 5-160 parts of lucid ganoderma, 1-90 parts of fermented cordyceps sinensis powder and 5-90 parts of roses. Or 5-150 parts of American ginseng, 5-160 parts of lucid ganoderma, 1-60 parts of cordyceps sinensis and 5-90 parts of rose. The traditional Chinese medicine composition provided by the invention can improve weight loss related to tumors, inhibit tumor growth, recover food intake, improve the athletic ability of a patient, relieve muscle and fat atrophy, inhibit spleen swelling, improve anemia and peripheral inflammation, and effectively relieve cancer-related fatigue caused by colon cancer, so that the traditional Chinese medicine composition provided by the invention has the advantages that the effect is obvious; the traditional Chinese medicine composition can be used for effectively treating colon cancer and malignant fluid, and has a wide application prospect in preparation of products for treating colon cancer and malignant fluid.

The invention discloses copper selenide / tricalcium silicate bone cement. The bone cement comprises a liquid phase component and a solid phase component, the liquid phase component is water, and the solid phase component is tricalcium silicate powder and copper selenide nanoparticles. Compared with the existing tricalcium silicate bone cement, the tricalcium silicate bone cement has the advantages that by introducing a trace amount of copper selenide nanoparticles, not only can the hydration and coagulation time of tricalcium silicate be shortened, but also the porosity and degradation rate of the tricalcium silicate after coagulation and solidification can be reduced, the compressive strength can be improved, the stimulation effect on ALP activity of MC3T3-E1 cells can be enhanced, the survival rate of the MC3T3-E1 cells can be improved, and the application prospect is broad. The immunogenic apoptosis of K7M2-wt cells is promoted, and the tumor growth rate is reduced. Besides, the introduction of the copper selenide nanoparticles can also endow the tricalcium silicate bone cement with the performance of temperature rise under near-infrared light, so that in clinical application, the tricalcium silicate bone cement can be further combined with a near-infrared technology to realize ablation of bone tumors, and a new strategy is provided for treatment of the bone tumors.

The application belongs to the technical field of biotechnology and gene therapy, and particularly relates to application of SNIP1 protein as a target in preparation or screening of an antitumor drug. The application finds that the SNIP1 protein is a non-histone substrate of lysine methyltransferase KMT5A, which promotes breast cancer cell growth, invasion and lung metastasis through KMT5A-mediated K301 monomethylation; therefore, the SNIP1 protein can be used as a target for screening of an antitumor drug, and a drug obtained by screening and inhibiting methylation of the K301 site of the SNIP1 protein can be used for antitumor; and the application provides a polypeptide specifically combined with the K301 site of the SNIP1 protein, the polypeptide is combined with the K301 site of the SNIP1 protein, inhibits methylation of the SNIP1 protein, and finally can inhibit tumor growth, proliferation, invasion and metastasis, and can be used as a new targeted antitumor drug.

The invention discloses an application of recombinant human copper / zinc superoxide dismutase in preparation of a medicine for treating triple negative breast cancer. The amino acid sequence of the recombinant human copper / zinc superoxide dismutase is shown as SEQ ID NO.1. The invention further discloses a preparation method of the recombinant human copper / zinc superoxide dismutase. The medicine for treating the triple negative breast cancer contains recombinant human copper / zinc superoxide dismutase. The medicine for treating the triple-negative breast cancer, which is prepared by recombining and transforming the human copper / zinc superoxide dismutase, can effectively control in-vitro migration of a triple-negative breast cancer cell line and tumor growth of a triple-negative breast cancer tumor-bearing mouse, so that the lifetime of the tumor-bearing mouse is effectively prolonged; therefore, the medicine for treating the triple-negative breast cancer has a very positive effect on treatment of the triple-negative breast cancer.

The invention provides a construction method and application of a transgenic animal model with osteoclast specific deletion, and belongs to the technical field of gene engineering. The invention provides a method for constructing an animal model of an osteoclast expression diphtheria toxin receptor, and particularly provides a method for constructing the animal model of the osteoclast expression diphtheria toxin receptor by using a Cre-loxP method. According to the method, the diphtheria toxin receptor is specifically expressed in the osteoclast, and the osteoclast can be specifically deleted by injecting the diphtheria toxin. The animal model of the osteoclast expression diphtheria toxin receptor prepared by the method can stably inherit after being established, is economical and reliable, can provide important theoretical and practical guidance for bone tumor treatment, also provides powerful animal model support for research of bone tumor growth correlation, and has a wide application prospect. Technical conditions are provided for screening, developing, preventing or treating medicines for bone tumors.

The invention discloses an application of 2, 3-dihydroxybenzoic acid in preparation of an antitumor drug. Researches find that 2, 3-dihydroxybenzoic acid can inhibit proliferation, migration and invasion of colorectal cancer cells in vitro and promote cell cycle arrest and cell apoptosis, and 2, 3-dihydroxybenzoic acid can inhibit growth of mouse transplanted tumors in vivo and promote cell apoptosis; the 2, 3-dihydroxybenzoic acid has a remarkable treatment effect on mouse colon cancer and can improve the immunotherapy effect; moreover, the 2, 3-dihydroxybenzoic acid small molecule substance, as an inhibitor of fatty acid synthase (FASN), plays an important role in inhibiting colorectum.

The invention provides a preparation method of a fragmented tumor antigen. The preparation method comprises the following steps: obtaining a tumor cell suspension; and irradiating and incubating the tumor cell suspension to prepare the fragmented tumor antigen. The preparation method is simple, low in cost and convenient to store, the fragmented tumor antigen prepared through the preparation method can remarkably inhibit tumor growth in vivo after being inoculated to an individual, tumor metastasis and relapse can also be effectively inhibited, immune memory is induced to be generated, the continuous anti-tumor effect is achieved, and the preparation method is suitable for clinical application. The control on metastatic tumors is obviously improved. The effective anti-tumor effect can be achieved in vivo when the fragmented tumor antigen prepared by the invention is independently or jointly used.

The invention relates to the field of tumor growth prediction, and discloses a tumor growth prediction method and system based on digital twinning, and the method comprises the steps: constructing a first digital twinning model of brain image data, clinical data and physiological data of a patient; constructing a second digital twinborn model of the blood brain barrier data, the drug interaction data and the dynamic microenvironment data of the patient; determining a first treatment prediction result according to the treatment scheme of the patient through the first digital twinborn model; determining a second treatment prediction result according to the treatment scheme of the patient through a second digital twinborn model; and through a treatment scheme correction model, according to the treatment scheme of the patient, the first treatment prediction result and the second treatment prediction result, determining a correction treatment scheme of the patient. The accuracy of tumor growth prediction is improved through the pharmacokinetic model, interaction mechanism simulation between drugs and dynamic microenvironment parameters.

The present application relates to a kind of pH / H2O2 dual-response drug-loaded hydrogel and its preparation method and application, by ε-polylysine derivative as antitumor active ingredient, with oxidized dextran through Schiff base reaction crosslinking rapid gelation. While using 2-formylphenyl boronic acid covalently package CD73 small molecule inhibitor APCP. ε-polylysine derivative has oncolytic activity, can induce ICD and promote the infiltration of immune cells in tumor cells. CD73 small molecule inhibitor APCP can block extracellular CD39-CD73-adenosine pathway, reduce the level of immunosuppressive metabolite adenosine in tumor tissue, so as to activate the infiltrated immune cells, restore its anti-tumor function. The hydrogel of ε-polylysine derivative and APCP co-delivery synergistically inhibits the effect of tumor growth, and its curative effect is greater than the treatment effect of single drug, and is superior to positive control drug oxaliplatin (OXA). The pH / H2O2 dual-response hydrogel is rapidly gelled, and has good biological safety under mild reaction conditions.

The present disclosure relates to anti-CD28 antibodies that bind to human CD28 and antigen-binding fragments thereof, compositions comprising same, and uses thereof in delaying and / or preventing tumor growth.

The invention relates to the technical field of medical nano-materials, and discloses a pH-responsive drug self-delivery nano-system and a preparation method and application thereof.The preparation method comprises the steps that 1, CMNPs is prepared, specifically, through an amidation reaction, the CMNPs are prepared from methotrexate and cis-aconitic anhydride; step 2, synthesizing DSPE-PEG-T12: synthesizing the DSPE-PEG-T12 by virtue of a nucleophilic addition reaction; step 3, preparing a T12 peptide modified erythrocyte membrane; and step 4, preparing T12-RBCM (at) CMNPs: modifying the T12 peptide of the targeted tumor cell transferrin receptor on an erythrocyte membrane, and coating the CMNPs to construct the nano-acquisition system T12-RBCM (at) CMNPs. According to the nano system T12-RBCM (at) CMNPs obtained by the scheme, the tumor cell uptake efficiency can be remarkably improved, cell apoptosis is induced, and proliferation is inhibited; the long-acting circulation and tumor targeting capability is realized, the tumor growth can be effectively inhibited, and the biological safety is good.

The invention discloses an application of neomycin in preparation of a medicine for treating tumors, and experiments show that tumor growth can be significantly inhibited by inhibiting interference of LPS (Lipopolysaccharide) on an STING pathway. The invention further provides a pharmaceutical composition containing the neomycin and the STING agonist (such as diABZI, cGAMP or CMA), the neomycin and the STING agonist show a synergistic effect in tumor resistance, the composition can be used for preparing drugs for treating tumors such as melanoma and colon cancer, and it is indicated that the neomycin or the combination of the neomycin and the STING agonist has wide application prospects in the medical field.

The application provides a radionuclide nanohydrogel microneedle and a preparation method and application thereof, and belongs to the field of nanobiomedicine. 32 P-labeled calcium phosphate, which is formed by a biomimetic reaction of Ag2S@Ca 32 P nanoparticles, and a base layer which is a base matrix and comprises hyaluronic acid 32 P nanohydrogel microneedle can release Ag2S nanoparticles in response to a weakly acidic tumor environment, and under the irradiation of near-infrared light, the photothermal conversion efficiency can effectively kill bacteria, effectively improve the tumor hypoxic environment, enhance the treatment effect of radionuclides, play an antibacterial and wound healing promoting role in melanoma defect repair, and maximize the inhibition of tumor growth and tumor recurrence.

Metastatic uveal melanomas are highly resistant to all existing treatments. To identify actionable vulnerabilities, the inventors conducted a CRISPR-Cas9 knockout screen using a library composed of chromatin remodelers. They revealed that the histone H3 methyltransferase SETDB1 plays a critical role in metastatic uveal melanoma cell proliferation and survival. Functionally, SETDB1 knockdown triggers decreased expression of genes related to replication and cell cycle and promotes growth arrest associated with increased markers for DNA damage and senescence entry. Using pre-clinical model, they further demonstrated that anti-SETDB1 therapy tumor growth in vivo. The inventors identify SETDB1 as a new relevant therapeutic target for the treatment of metastatic uveal melanomas. The present invention relates to a method for treating uveal melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of SETDB1 inhibitor.

The present invention relates to the technical field of traditional Chinese medicine. Disclosed is use of zedoarondiol in the preparation of a drug for preventing, treating, and inhibiting lung cancer. It has been discovered that zedoarondiol can effectively induce apoptosis of A549 cells, inhibit the growth of non-small cell lung cancer, significantly inhibit the migration of A549 cells, hinder the development of non-small cell lung cancer, and simultaneously inhibit tumor growth. The present invention provides new use of zedoarondiol, expanding the medical application of zedoarondiol and offering a new technical means for lung cancer treatment.

The invention belongs to the technical field of biological medicine and molecular biology, and provides application of GJB6 in preparation of an esophageal squamous cell carcinoma prognosis evaluation reagent and screening of drugs for targeted treatment of esophageal squamous cell carcinoma. The low expression of the GJB6 is applied to preparation of an esophageal squamous cell carcinoma prognosis evaluation reagent. GJB6 is low in expression in ESCC patients, and ESCC prognosis is poor. And the prognosis of patients with high expression of GJB6 is better. Overexpression of GJB6 inhibits ESCC cell proliferation, migration and invasion and in-vivo tumor enlargement. The GJB6 plays a role of a cancer suppressor gene in ESCC and inhibits cell proliferation, migration and invasion. The AKT signal channel is one of downstream channels for GJB6 to regulate the occurrence and development of ESCC. The AKT inhibitor effectively inhibits GJB6 low-expression ESCC malignant phenotypes, including enhancement of cell proliferation and migration invasion ability and in-vivo tumor enlargement. The AKT is a key therapeutic target of the GJB6 low expression type ESCC.